Search Result

Results for "

LTD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) Cytochrome P450 (2) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (8) Histamine Receptor (2) iGluR (3) Isotope-Labeled Compounds (5) Leukotriene Receptor (54) LPL Receptor (2) mGluR (2) P-glycoprotein (2) Phospholipase (1) PKC (1) Platelet-activating Factor Receptor (PAFR) (1) PPAR (3) Prostaglandin Receptor (4) Reference Standards (5)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Endocrinology (3) Inflammation/Immunology (52) Metabolic Disease (3) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19989

MK-571 Maximum Cited Publications 33 Publications Verification L-660711	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) is an orally active, potent and selective competitive *leukotriene D₄ (LTD₄)* receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1)** inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-19989A

MK-571 sodium Maximum Cited Publications 33 Publications Verification L-660711 sodium	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) sodium is an orally active, potent and selective competitive *leukotriene D₄ (LTD₄)* receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1)**. MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-B0290

Pranlukast 3 Publications Verification ONO-1078	Leukotriene Receptor Endogenous Metabolite	Inflammation/Immunology
Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-113465

Leukotriene E4 1 Publications Verification LTE4	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-B0290A

Pranlukast hemihydrate 3 Publications Verification ONO-1078 hemihydrate	Leukotriene Receptor Endogenous Metabolite	Inflammation/Immunology
Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-156978

Ritolukast Wy-48252	Leukotriene Receptor	Others
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD₄/E₄) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD₄ in guinea pigs, with an ID₅₀ of 0.5mg/kg .

HY-B0290R

Pranlukast (Standard) ONO-1078 (Standard)	Reference Standards Leukotriene Receptor Endogenous Metabolite	Inflammation/Immunology
Pranlukast (Standard) is the analytical standard of Pranlukast. This product is intended for research and analytical applications. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-107508

VU-29	mGluR	Neurological Disease
VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC₅₀=9 nM and K_i=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC₅₀: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .

HY-101676

RG-12525 NID 525	Leukotriene Receptor PPAR Cytochrome P450	Metabolic Disease
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, *LTD4* and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-113465S

Leukotriene E4-d5 LTE4-d₅	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4-d₅ is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-127115

Sulukast LY 170680	Leukotriene Receptor	Inflammation/Immunology
Sulukast (LY 170680) is a selective leukotriene D₄ (LTD₄) antagonist. Sulukast exerts an effective antagonistic effect on bronchoconstriction induced by *LTD₄*. Sulukast can be used in the research of diseases such as asthma .

HY-176921

ONO-2570366	Leukotriene Receptor	Inflammation/Immunology
ONO-2570366 (Compound 11a) is an antagonist of the cysteinyl leukotriene receptors CysLT1R and CysLT2R (IC₅₀ = 14 nM). ONO-2570366 inhibits the binding of LTD_{4 (the main active form of CysLTs) to CysLT1R/CysLT2R by stabilizing the inactive receptor conformation, thereby preventing the Gq signaling pathway mediated by receptor activation. ONO-2570366 can be used for the researches of inflammation and immunology, such as asthma .}

HY-105712

CGP 57698	Leukotriene Receptor	Inflammation/Immunology
CGP 57698 is an efficient CysLT receptor (K_i = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions .

HY-17492R

Zafirlukast (Standard) ICI 204219 (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-176920

BRI-12349	Leukotriene Receptor	Inflammation/Immunology
BRI-12349 (Compound 50) is a dual antagonist of CysLT1R/CysLT2R with K_i values of 1.03 and 6.46 μM. BRI-12349 can inhibit the generation of IP₁ induced by LTD₄ (the main ligand of CysLTs). BRI-12349 can be used for the research of immunology and inflammation, such as asthma .

HY-U00359

LTD4 antagonist 1	Leukotriene Receptor	Inflammation/Immunology
LTD₄ antagonist 1 is a potent, orally active antagonist of leukotriene D₄ (LTD₄) with a K_i of 0.57 nM.

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel *leukotriene D4 (LTD4)/thromboxane A2 (TxA2)* dual receptor antagonist, with antiasthmatic activities.

HY-101731

CP-96021 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
CP-96021 hydrochloride is a balanced, combined, potent and orally active *leukotriene D4 (LTD4)/platelet activating factor (PAF)* receptor antagonist with K_i values of 34 nM and 37 nM, respectively .

HY-U00364

CI-949	Histamine Receptor Prostaglandin Receptor Leukotriene Receptor	Inflammation/Immunology Endocrinology
CI-949 is an allergic mediator release inhibitor, which inhibits histamine, leukotriene C₄/D₄ (LTC₄/LTD₄), and thromboxane B₂ (TXB₂) release with IC₅₀s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.

HY-N16543

Bisisorhapontigenin A	Leukotriene Receptor	Inflammation/Immunology
Bisisorhapontigenin A is a dimer of isorhapontigenin. Bisisorhapontigenin A exhibits antagonistic activity against *LTD4* and can be used for research on anti-inflammatory effects .

HY-122149

L-648051	Leukotriene Receptor	Cardiovascular Disease
L-648051 is a leukotriene D4 receptor (LTD4) antagonist. L-648051 plays an important role in arrhythmias .

HY-101946

AS-35	Leukotriene Receptor	Inflammation/Immunology
AS-35 is an orally effective, potent and selective antagonist of leukotrienes, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC₅₀ values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.

HY-105483

MDL 43291	Leukotriene Receptor	Inflammation/Immunology
MDL 43291 is a competitive leukotriene (LT) receptor antagonist. MDL 43291 antagonize *LTD4* and LTE4 with pA2 of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma .

HY-B0290AR

Pranlukast hemihydrate (Standard) ONO-1078 hemihydrate (Standard)	Leukotriene Receptor Endogenous Metabolite Reference Standards	Inflammation/Immunology
Pranlukast (hemihydrate) (Standard) is the analytical standard of Pranlukast (hemihydrate). This product is intended for research and analytical applications. Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-101235

ICI 185282	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD₂ (HY-101988), PGF_2α (HY-12956), arachidonic acid (HY-109590), LTD₄ and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research .

HY-19178

LTD4 antagonist 3 FK011 hydrochloride	Leukotriene Receptor PPAR	Inflammation/Immunology
LTD4 antagonist 3 (FK011 hydrochloride) is a *LTD₄* antagonist. LTD4 antagonist 3 has agonistic activity for PPAR-γ, with a fold-increase of 1.50 at 1 μM and 2.35 at 10 μM. LTD4 antagonist 3 can be used of development of non-steroidal anti-inflammatory drugs (NSAIDs) .

HY-W747563

11-trans Leukotriene D4 11-trans LTD4	Drug Isomer	Others
11-trans Leukotriene D4 (11-trans LTD4) is a C-11 double bond isomer of LTD4. LTD4 undergoes slow temperature-dependent isomerization to 11-trans LTD4 during storage. 11-trans LTD4 retains about 10-25 % of the potency for contraction of guinea pig ileum, trachea and parenchyma compared to LTD4. It exhibits an ED50 ranging between 12-60 nM for contraction of guinea pig trachea.

HY-N8892

Triptinin B	Leukotriene Receptor	Others
Triptinin B (compound 2) is a *LTD₄* antagonist that can be isolated from Tripterygium wilfordii .

HY-168784

LTD4 antagonist 2	Leukotriene Receptor	Metabolic Disease Inflammation/Immunology
LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC₅₀ of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-137493

14,15-Leukotriene D4 14,15-LTD4; Eoxin D4	Endogenous Metabolite	Inflammation/Immunology
14,15-Leukotriene D4 (14,15-LTD4) is a leukotriene that producted by eosinophils with Arachidonic acid (HY-109590), and through the 15-lipoxygenase-1 pathway .

HY-113758

LY 163443	Leukotriene Receptor	Inflammation/Immunology
LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4). LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4 .

HY-100316

CP-96486	Leukotriene Receptor	Inflammation/Immunology
CP-96486 is a potent and orally active leukotriene D₄ (LTD₄)/platelet activating factor (PAF) receptor antagonist with K_is of 20 and 24 nM, respectively.

HY-136831

SR2640 QMPB	Leukotriene Receptor	Inflammation/Immunology
SR2640 is a highly efficient and selective *LTD4/LTE4* antagonist that can specifically inhibit the smooth muscle contractions induced by *LTD4* in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] *LTD4* to membrane receptors in guinea pig lung tissue, with an IC₅₀ of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous *LTD4* in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research .

HY-120755

LY290324	Leukotriene Receptor	Inflammation/Immunology
LY290324 is a potent and orally active leukotriene D4 (LTD4) antagonist. LY290324 reduces LTC4, LTD4 and LTE4 (HY-113465)-induced bronchospasm. LY290324 has the potential for the research of antigen-induced bronchospasm .

HY-125408

Maresin conjugates in tissue regeneration 1 MCTR1	Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
Maresin conjugates in tissue regeneration 1 (MCTR1) is a potent cytokine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the inflammatory response and promotes tissue regeneration. Maresin conjugates in tissue regeneration 1 antagonize LTD4-stimulated vascular responses .

HY-113693

ONO-RS-347	Leukotriene Receptor	Others
ONO-RS-347 is an orally active and potent antagonist of leukotriene C4 and D4. ONO-RS-347 inhibits *LTD4*-induced bronchoconstriction in guinea pigs. ONO-RS-347 is promising for research of allergic asthma and other immediate hypersensitivty diseases .

HY-19161

Bay-X-7195	Leukotriene Receptor	Inflammation/Immunology
Bay-X-7195 is a CYS leukotriene 1 receptor (CYS LT1) antagonist. Bay-X-7195 shows an antagonistic action to LTD4-induced bronchoconstriction in vitro and in vivo. Bay-X-7195 can be used foe the study of allergic and asthmatic .

HY-105221

Masilukast ZD-3523	Leukotriene Receptor	Inflammation/Immunology
Masilukast is an orally administered *cysteinyl leukotriene D₄ (LTD₄)* receptor** antagonist with potential to research asthma.

HY-100724

YM-17690	Leukotriene Receptor	Inflammation/Immunology
YM-17690 is a *LTD₄* and LTE₄ agonist, with a pK_i value of 9.28 for [3H]LTD₄. It induces dose-dependent contractions in guinea pig ileum, lung parenchyma, and trachea, with EC₅₀ values of 16, 3.9, and 22 nM, respectively. YM-17690 can be used in research related to asthma and inflammation .

HY-19041

CGP-35949 sodium	Phospholipase Leukotriene Receptor	Inflammation/Immunology
CGP-35949 sodium is a *LTD4* antagonist with phospholipase inhibitory activity. CGP-35949 sodium can be used for research of asthma .

HY-115356

Eoxin E4 14,15-LTE4; EoxE4	Drug Metabolite	Cardiovascular Disease
Eoxin E4 (14,15-LTE₄) is the metabolite of 14,15-LTC₄ and 14,15-LTD₄. Eoxin E4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency than LTC₄, but approximately 100-fold greater potency than histamine .

HY-163101

CP-96021	Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor	Inflammation/Immunology
CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) receptor antagonist, featuring a guinea pig LTD4 receptor K_i of 34 nM and a rabbit PAF receptor K_i of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma .

HY-130138A

(5S,6R)-DiHETE	Leukotriene Receptor	Inflammation/Immunology
(5S,6R)-DiHETE is an enantiomer of (5,6)-DiHETEs. (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC₅₀ of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .

HY-U00355

YM158 free base YM-57158	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
YM158 free base is a potent and selective *LTD₄* and TXA₂ receptor antagonist with pA₂ values of about 8.87 and 8.81, respectively.

HY-19241

CP-85958	Leukotriene Receptor	Inflammation/Immunology
CP-85958 is a specific leukotriene D₄ (LTD₄) receptor antagonist. CP-85958 can be used in the research of inflammatory diseases such as asthma .

HY-120486

LY203647	Leukotriene Receptor	Inflammation/Immunology
LY203647 is an orally active antagonist for leukotriene receptor *LTD4* and LTE4. LY203647 can be used in research about asthma and other inflammation diseases .

HY-107611

Ro 24-5913 Cinalukast	Leukotriene Receptor	Inflammation/Immunology
Ro 24-5913 (Cinalukast) is an orally active and potent *LTD4* antagonist with an IC₅₀ value of 6.4 nM. Ro 24-5913 can be used for the research of asthma .

HY-130138B

(5S,6R)-DiHETEs (5S,6R)-(11E)-DiHETE	Leukotriene Receptor	Inflammation/Immunology
(5S,6R)-DiHETEs is the isomer of (5S,6R)-DiHETE (HY-130138A). (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC₅₀ of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .

HY-118958

Ablukast Ro 23-3544	Leukotriene Receptor	Inflammation/Immunology
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction . Ablukast is LTD4 receptor antagonist .

Cat. No.	Product Name	Target	Research Area

HY-P4106A

Tat-GluR23Y, scrambled TFA 1 Publications Verification	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-P4106

Tat-GluR23Y, scrambled	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-P1058

Pep2m	iGluR	Neurological Disease
Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression ^{[1] [2] [3] [4] [5]}.

HY-P1056

pep2-SVKI	iGluR	Neurological Disease
pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0290

Pranlukast 3 Publications Verification ONO-1078	Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Leukotriene Receptor Endogenous Metabolite
Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-113465

Leukotriene E4 1 Publications Verification LTE4	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-B0290A

Pranlukast hemihydrate 3 Publications Verification ONO-1078 hemihydrate	Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Leukotriene Receptor Endogenous Metabolite
Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-B0290R

Pranlukast (Standard) ONO-1078 (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Leukotriene Receptor Endogenous Metabolite
Pranlukast (Standard) is the analytical standard of Pranlukast. This product is intended for research and analytical applications. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ ³H]LTE₄, [ ³H]LTD₄, and [ ³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-N16543

Bisisorhapontigenin A	Structural Classification Phenols Polyphenols Gnetaceae Plants Gnetum montanum Markgr. Source Classification	Leukotriene Receptor
Bisisorhapontigenin A is a dimer of isorhapontigenin. Bisisorhapontigenin A exhibits antagonistic activity against *LTD4* and can be used for research on anti-inflammatory effects .

HY-B0290AR

Pranlukast hemihydrate (Standard) ONO-1078 hemihydrate (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Leukotriene Receptor Endogenous Metabolite Reference Standards
Pranlukast (hemihydrate) (Standard) is the analytical standard of Pranlukast (hemihydrate). This product is intended for research and analytical applications. Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-N8892

Triptinin B	Triterpenes Terpenoids Celastraceae Plants Tripterygium wilfordii Hook. f. Source Classification	Leukotriene Receptor
Triptinin B (compound 2) is a *LTD₄* antagonist that can be isolated from Tripterygium wilfordii .

Cat. No.	Product Name	Chemical Structure

HY-113465S

Leukotriene E4-d5
Leukotriene E4-d₅ is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-17492S

Zafirlukast-d7
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects .

HY-17492S3

Zafirlukast-d6
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-B0290S1

Pranlukast-d4
Pranlukast-d₄ is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LTD

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products